M S Ernstoff - JoVE Visualize

Showing results (71-80 of 85) with videos related to

Pageof 9

Sort By:

Journal of Immunological Methods|February 27, 2001

Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class IP K Wallace, K Y Tsang, J Goldstein, et al.

Melanoma Research|December 1, 1993

Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. The Tissue Bank, Pittsburgh Cancer InstituteT F Logan, W Shannon, J Bryant, et al.

Cancer Research|February 15, 1992

Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trialM S Ernstoff, W Gooding, S Nair, et al.

The Journal of Urology|March 29, 2000

A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parametersT Schwaab, J A Heaney, A R Schned, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1987

Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018)J M Kirkwood, R D Neumann, S S Zoghbi, et al.

Journal of Hematotherapy|October 1, 1995

Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neuF H Valone, P A Kaufman, P M Guyre, et al.

Proceedings of the National Academy of Sciences of the United States of America|November 1, 1992

Homozygous deletions within human chromosome band 9p21 in melanomaJ W Fountain, M Karayiorgou, M S Ernstoff, et al.

Melanoma Research|October 1, 1995

Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-upS C Lattanzi, T Tosteson, J Chertoff, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190J M Kirkwood, J G Ibrahim, V K Sondak, et al.

Journal of Immunological Methods|February 27, 2001

Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neuL D Lewis, B F Cole, P K Wallace, et al.

Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:

Pageof 9

Journal of Immunological Methods|February 27, 2001

Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class IP K Wallace, K Y Tsang, J Goldstein, et al.

Melanoma Research|December 1, 1993

Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. The Tissue Bank, Pittsburgh Cancer InstituteT F Logan, W Shannon, J Bryant, et al.

Cancer Research|February 15, 1992

Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trialM S Ernstoff, W Gooding, S Nair, et al.

The Journal of Urology|March 29, 2000

A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parametersT Schwaab, J A Heaney, A R Schned, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1987

Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018)J M Kirkwood, R D Neumann, S S Zoghbi, et al.

Journal of Hematotherapy|October 1, 1995

Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neuF H Valone, P A Kaufman, P M Guyre, et al.

Proceedings of the National Academy of Sciences of the United States of America|November 1, 1992

Homozygous deletions within human chromosome band 9p21 in melanomaJ W Fountain, M Karayiorgou, M S Ernstoff, et al.

Melanoma Research|October 1, 1995

Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-upS C Lattanzi, T Tosteson, J Chertoff, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190J M Kirkwood, J G Ibrahim, V K Sondak, et al.

Journal of Immunological Methods|February 27, 2001

Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neuL D Lewis, B F Cole, P K Wallace, et al.

Pageof 9